US2012003260A1PendingUtilityA1
Solid-Phase and Solution-Phase Synthesis of Glycosylphosphatidylinositol Glycans
Individually held — no corporate assignee on recordPriority: Jul 10, 2002Filed: May 17, 2011Published: Jan 5, 2012
Est. expiryJul 10, 2022(expired)· nominal 20-yr term from priority
C07H 15/207C07H 15/203C08B 37/006A61P 33/02A61P 37/04
46
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof.
Claims
exact text as granted — not AI-modified1 . Compound 2
2 . A conjugate comprising a glycosylphosphatidylinositol (GPI) fragment covalently linked to a protein.
3 . The conjugate of claim 2 , wherein the GPI fragment is compound 2
4 . The conjugate of claim 2 , wherein the GPI fragment is covalently linked to the protein through a sulfhydryl-maleimide linker.
5 . The conjugate of claim 4 , wherein the conjugate is
6 . (canceled)
7 . The conjugate of claim 2 , wherein the protein is albumin.
8 - 12 . (canceled)
13 . A vaccine comprising an immunogenic amount of a conjugate comprising a glycosylphosphatidylinositol (GPI) fragment covalently linked to a protein.
14 . The vaccine of claim 13 , wherein the GPI fragment is compound 2
15 . The vaccine of claim 13 , wherein the GPI fragment is covalently linked to the protein through a sulfhydryl-maleimide linker.
16 . The vaccine of claim 15 , wherein the conjugate is
17 . (canceled)
18 . The vaccine of claim 13 , wherein the protein is albumin.
19 - 25 . (canceled)
26 . A compound selected from the group consisting of:Join the waitlist — get patent alerts
Track US2012003260A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.